NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.

[1]  A. Belger,et al.  Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions , 2000, Biological Psychiatry.

[2]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[3]  K. Rasmussen,et al.  The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal , 1999, Neuropharmacology.

[4]  J. Krystal,et al.  D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. , 1998, Biological psychiatry.

[5]  B. Moghaddam,et al.  Glutamatergic Regulation of Basal and Stimulus‐Activated Dopamine Release in the Prefrontal Cortex , 1998, Journal of neurochemistry.

[6]  K. Black,et al.  Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[8]  P. Blanchet,et al.  Neostriatal mechanisms in Parkinson's disease , 1998, Neurology.

[9]  M. Schachner,et al.  Molecular mechanisms that underlie structural and functional changes atthe postsynaptic membrane duringsynaptic plasticity , 1998, Progress in Neurobiology.

[10]  J. Krystal,et al.  The NMDA antagonist model for schizophrenia: promise and pitfalls. , 1998, Pharmacopsychiatry.

[11]  T. Chase,et al.  Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease , 1998, Neurology.

[12]  N. Fountain,et al.  Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. , 1998, Journal of Neurophysiology.

[13]  Takayoshi Kobayashi,et al.  Cocaine: evidence for NMDA-, β-carboline- and dopaminergic-mediated seizures in mice , 1998, Brain Research.

[14]  J. Coyle,et al.  Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. , 1998, The American journal of psychiatry.

[15]  R. Gracely,et al.  Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. , 1998, Anesthesia and analgesia.

[16]  M. MacDonald,et al.  Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.

[17]  D. Javitt,et al.  The role of N-Methyl-D-Aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes , 1998, European Neuropsychopharmacology.

[18]  W. Falk,et al.  A preliminary study of D-cycloserine treatment in Alzheimer's disease. , 1998, The Journal of neuropsychiatry and clinical neurosciences.

[19]  H. Monyer,et al.  Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors. , 1998, The Journal of biological chemistry.

[20]  P. Calabresi,et al.  Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease , 1998, Annals of neurology.

[21]  P. Goldman-Rakic,et al.  204. Glutamate, dopamine, the frontal cortex, and schizophrenia , 1998, Biological Psychiatry.

[22]  J. Krystal,et al.  Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. , 1998, Archives of general psychiatry.

[23]  G. Lynch,et al.  Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Correlations with Hippocampal Neuronal Activity , 1998, The Journal of Neuroscience.

[24]  G. McCarthy,et al.  Assessment of prefrontal activation by infrequent visual targets and non-target novel stimuli in schizophrenia: A functional MRI study , 1998, Schizophrenia Research.

[25]  A. Rice,et al.  NMDA receptor activation during status epilepticus is required for the development of epilepsy , 1998, Brain Research.

[26]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.

[27]  M. Wolf,et al.  Amphetamine and D1 Dopamine Receptor Agonists Produce Biphasic Effects on Glutamate Efflux in Rat Ventral Tegmental Area: Modification by Repeated Amphetamine Administration , 1998, Journal of neurochemistry.

[28]  J. Krystal,et al.  601 Glycine ketamine interactions in healthy humans , 1997, Schizophrenia Research.

[29]  G. Konopka,et al.  Mechanism and prevention of neurotoxicity caused by β-amyloid peptides: relation to Alzheimer's disease , 1997, Brain Research.

[30]  U. Frey,et al.  Hippocampal synaptic plasticity: role in spatial learning or the automatic recording of attended experience? , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[31]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[32]  J. Olney,et al.  Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. , 1997, Archives of neurology.

[33]  P. Eide,et al.  Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery , 1997, Acta anaesthesiologica Scandinavica.

[34]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[35]  J. Witkin,et al.  Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice , 1997, Psychopharmacology.

[36]  A. Stubhaug,et al.  Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo , 1997, PAIN.

[37]  N L Foster,et al.  Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease , 1997, Neurology.

[38]  J. Yakel Calcineurin regulation of synaptic function: from ion channels to transmitter release and gene transcription. , 1997, Trends in pharmacological sciences.

[39]  Roberto Malinow,et al.  Learning Mechanisms: The Case for CaM-KII , 1997, Science.

[40]  C. Applegate,et al.  Effects of Valproate, Phenytoin, and MK‐801 in a Novel Model of Epileptogenesis , 1997, Epilepsia.

[41]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[42]  J. Davies Remacemide hydrochloride: a novel antiepileptic agent. , 1997, General pharmacology.

[43]  M. MacDonald,et al.  Huntingtin Immunoreactivity in the Rat Neostriatum: Differential Accumulation in Projection and Interneurons , 1997, Experimental Neurology.

[44]  J M Gorman,et al.  Mechanisms underlying memory impairment in schizophrenia , 1997, Psychological Medicine.

[45]  H S Chen,et al.  Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.

[46]  M. Weller,et al.  Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy , 1997, Biological Psychiatry.

[47]  R. Bronen,et al.  Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse—a preliminary report , 1997, Biological Psychiatry.

[48]  M. Delong,et al.  Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.

[49]  G. Aghajanian,et al.  A Selective AMPA Antagonist, LY293558, Suppresses Morphine Withdrawal-Induced Activation of Locus Coeruleus Neurons and Behavioral Signs of Morphine Withdrawal , 1996, Neuropsychopharmacology.

[50]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[51]  R. Spanagel,et al.  Evidence for alcohol anti-craving properties of memantine. , 1996, European journal of pharmacology.

[52]  S. Lipton,et al.  NMDA receptors: from genes to channels. , 1996, Trends in pharmacological sciences.

[53]  G. Freund,et al.  Glutamate receptors in the frontal cortex of alcoholics. , 1996, Alcoholism, clinical and experimental research.

[54]  C. Tamminga,et al.  Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. , 1996, Journal of psychiatric research.

[55]  Josep Rizo,et al.  Synaptotagmins: C2-Domain Proteins That Regulate Membrane Traffic , 1996, Neuron.

[56]  K. Mann,et al.  Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. , 1996, Archives of general psychiatry.

[57]  S. Woods,et al.  A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. , 1996, European journal of pharmacology.

[58]  S. Mercadante Ketamine in cancer pain: an update. , 1996, Palliative medicine.

[59]  N. Cairns,et al.  Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. , 1996, Dementia.

[60]  C. J. Schmidt,et al.  Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. , 1996, The Journal of pharmacology and experimental therapeutics.

[61]  D. Schroeder,et al.  Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.

[62]  W. Fleischhacker,et al.  Comparison of acamprosate and placebo in long-term treatment of alcohol dependence , 1996, The Lancet.

[63]  M. Mcdermott,et al.  A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[64]  Herbert Weingartner,et al.  NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.

[65]  A. Alterman,et al.  Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. , 1996, Drug and alcohol dependence.

[66]  M. Hasselmo,et al.  NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  G. Lynch,et al.  Psychological effects of a drug that facilitates brain AMPA receptors , 1996, International clinical psychopharmacology.

[68]  S. Hashtroudi,et al.  d-Cycloserine enhances implicit memory in Alzheimer patients , 1996, Neurology.

[69]  K. Fukunaga,et al.  A role of Ca2+/calmodulin-dependent protein kinase II in the induction of long-term potentiation in hippocampal CA1 area , 1996, Neuroscience Research.

[70]  Joseph T. Coyle,et al.  The Glutamatergic Dysfunction Hypothesis for Schizophrenia , 1996, Harvard review of psychiatry.

[71]  E. Nestler,et al.  Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[72]  S. Potkin,et al.  Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[73]  J. P. Apland,et al.  Anticonvulsant effects of memantine and MK-801 in Guinea Pig hippocampal slices , 1995, Brain Research Bulletin.

[74]  P. Stanton,et al.  Long-term potentiation and N-methyl-d-aspartate receptors: Foundations of memory and neurologic disease? , 1995, Neuroscience & Biobehavioral Reviews.

[75]  K. Rasmussen The Role of the Locus Coeruleus and N-Methyl-D-Aspartic Acid (NMDA) and AMPA Receptors in Opiate Withdrawal , 1995, Neuropsychopharmacology.

[76]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[77]  R. Huganir,et al.  Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions , 1995, Neuroreport.

[78]  R. Post,et al.  Stress, Conditioning, and the Temporal Aspects of Affective Disorders , 1995, Annals of the New York Academy of Sciences.

[79]  K. A. Trujillo Effects of Noncompetitive N-Methyl-D-Aspartate Receptor Antagonists on Opiate Tolerance and Physical Dependence , 1995, Neuropsychopharmacology.

[80]  R. Anwyl,et al.  beta-Amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hippocampus. , 1995, Neuroreport.

[81]  J. Dostrovsky,et al.  Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.

[82]  H. Kubová,et al.  Suppression of cortical epileptic afterdischarges by ketamine is not stable during ontogenesis in rats , 1995, Pharmacology Biochemistry and Behavior.

[83]  W H Theodore,et al.  Felbamate Monotherapy: Implications for Antiepileptic Drug Development , 1995, Epilepsia.

[84]  S. Heinemann,et al.  Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[85]  S. Akbarian,et al.  Developmental and regional expression pattern of a novel NMDA receptor- like subunit (NMDAR-L) in the rodent brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  R. Herting,et al.  Evaluation of Cycloserine in the Treatment of Alzheimer's Disease , 1995, Journal of geriatric psychiatry and neurology.

[87]  J. Krystal,et al.  Glycine Site Agonists of the NMDA Receptor: A Review , 1995 .

[88]  I. Feinberg,et al.  Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats , 1995, Neuroscience Letters.

[89]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[90]  S. Sagratella NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. , 1995, Pharmacological research.

[91]  S. Southwick,et al.  MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. , 1995, The American journal of psychiatry.

[92]  P. Kalivas,et al.  D1 receptors modulate glutamate transmission in the ventral tegmental area , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[93]  B. McEwen,et al.  Effects of adrenal steroid manipulations and repeated restraint stress on dynorphin mRNA levels and excitatory amino acid receptor binding in hippocampus , 1995, Brain Research.

[94]  N C Andreasen,et al.  Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms , 1995 .

[95]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[96]  J. Krystal,et al.  Differentiating nmda dysregulation in schizophrenia and alcoholism using ketamine , 1995, Schizophrenia Research.

[97]  G. Nowak,et al.  Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims , 1995, Brain Research.

[98]  J. Coyle,et al.  The glutamatergic basis of human alcoholism. , 1995, The American journal of psychiatry.

[99]  P. Kalivas,et al.  Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. , 1995, Drug and alcohol dependence.

[100]  H. Silver,et al.  Effects of Biperiden and Amantadine on Memory in Medicated Chronic Schizophrenic Patients , 1995, British Journal of Psychiatry.

[101]  G. Nowak,et al.  Swim Stress Increases the Potency of Glycine at the N‐Methyl‐d‐Aspartate Receptor Complex , 1995, Journal of neurochemistry.

[102]  R. Sofia,et al.  Felbamate modulates the strychnine-insensitive glycine receptor , 1995, Epilepsy Research.

[103]  F. Bloom,et al.  Psychopharmacology: The Fourth Generation of Progress , 1995 .

[104]  B. Moghaddam,et al.  Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: Implications for tonic influence of glutamate on dopamine release , 1994, Synapse.

[105]  B. Meldrum The role of glutamate in epilepsy and other CNS disorders , 1994, Neurology.

[106]  Y. Yoneda,et al.  Preferential Induction by Stress of the N‐Methyl‐d‐Aspartate Recognition Domain in Discrete Structures of Rat Brain , 1994, Journal of neurochemistry.

[107]  J. Joyce,et al.  Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[108]  M. Papp,et al.  Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. , 1994, European journal of pharmacology.

[109]  M. Millan,et al.  Chemically-diverse ligands at the glycine B site coupled to N-methyl-d-aspartate (NMDA) receptors selectively block the late phase of formalin-induced pain in mice , 1994, Neuroscience Letters.

[110]  R. Sapolsky,et al.  Glucocortcoids mediate the stress-induced extracellular accumulation of glutamate , 1994, Brain Research.

[111]  M. Bear,et al.  Synaptic plasticity: LTP and LTD , 1994, Current Opinion in Neurobiology.

[112]  R. Kurlan,et al.  Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.

[113]  Richard L. Huganir,et al.  Glutamate receptor phosphorylation and synaptic plasticity , 1994, Current Opinion in Neurobiology.

[114]  P. Skolnick,et al.  Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. , 1994, The Journal of pharmacology and experimental therapeutics.

[115]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[116]  G. Aghajanian,et al.  Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study , 1994, Brain Research.

[117]  P. Skolnick,et al.  Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. , 1993, European journal of pharmacology.

[118]  M. Papp,et al.  New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. , 1993, Polish journal of pharmacology.

[119]  G. Lynch,et al.  Corticosterone Exacerbates Kainate‐Induced Alterations in Hippocampal Tau Immunoreactivity and Spectrin Proteolysis In Vivo , 1993, Journal of neurochemistry.

[120]  J. Penney,et al.  NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex , 1993, Neurobiology of Aging.

[121]  T. Yamakura,et al.  Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. , 1993, Neuroreport.

[122]  P. Skolnick,et al.  Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. , 1993, The Journal of pharmacology and experimental therapeutics.

[123]  J. Korf,et al.  A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area , 1993, Neuroscience Letters.

[124]  B. Moghaddam,et al.  Stress Preferentially Increases Extraneuronal Levels of Excitatory Amino Acids in the Prefrontal Cortex: Comparison to Hippocampus and Basal Ganglia , 1993, Journal of neurochemistry.

[125]  W. Carlezon,et al.  D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. , 1993, Behavioral and neural biology.

[126]  W. Schmidt,et al.  D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. , 1992, European journal of pharmacology.

[127]  T. Kosten,et al.  Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. , 1992, Archives of general psychiatry.

[128]  J. Marshall,et al.  Elevated NMDA receptors in parkinsonian striatum. , 1992, Neuroreport.

[129]  A. Alterman,et al.  Amantadine may facilitate detoxification of cocaine addicts. , 1992, Drug and alcohol dependence.

[130]  R. Ehrman,et al.  Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. , 1992, Addictive Behaviours.

[131]  R. Sapolsky,et al.  Corticosterone Enhances Kainic Acid‐Induced Calcium Elevation in Cultured Hippocampal Neurons , 1992, Journal of neurochemistry.

[132]  C. Cotman,et al.  N-methyl-d-aspartate receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease , 1992, Neuroscience.

[133]  T. Chase,et al.  Glutamatergic therapy of Huntington's chorea. , 1992, Clinical neuropharmacology.

[134]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[135]  Karl J. Friston,et al.  Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.

[136]  J. Penney,et al.  Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of huntington's disease , 1991, Annals of neurology.

[137]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[138]  P. Slater,et al.  Binding to the glycine site of the NMDA receptor complex in brains of patients with Alzheimer's disease , 1991, Neuroscience Letters.

[139]  Greenamyre Jt,et al.  N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991 .

[140]  C. Haertzen,et al.  Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. , 1991, NIDA research monograph.

[141]  K. Perry,et al.  NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. , 1991, European journal of pharmacology.

[142]  A. Benabid,et al.  Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.

[143]  P. Francis,et al.  Characterisation of the Glycine Modulatory Site of the N‐Methyl‐d‐Aspartate Receptor‐Ionophore Complex in Human Brain , 1991, Journal of neurochemistry.

[144]  R. Faull,et al.  Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study , 1990, Neuroscience.

[145]  F. F. Weight,et al.  Inhibition of N-methyl-l-aspartate activated ion current by desmethylimipramine , 1990, Brain Research.

[146]  C. Cotman,et al.  β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage , 1990, Brain Research.

[147]  Robert M. Sapolsky,et al.  Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent , 1990, Brain Research.

[148]  P. Skolnick,et al.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. , 1990, European journal of pharmacology.

[149]  S. Gershon,et al.  Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[150]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[151]  Michael Davis,et al.  Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala , 1990, Nature.

[152]  G. Aghajanian,et al.  Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis , 1989, Brain Research.

[153]  P. Skolnick,et al.  Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors , 1989, Pharmacology, Biochemistry and Behavior.

[154]  J. Kornhuber,et al.  Regional distribution of [3H]MK-801 binding sites in the human brain , 1989, Brain Research.

[155]  G White,et al.  Ethanol inhibits NMDA-activated ion current in hippocampal neurons. , 1989, Science.

[156]  K. Grant,et al.  Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals , 1989, Pharmacology Biochemistry and Behavior.

[157]  R. Johnson,et al.  Excitatory amino acid neurotransmission. , 1988, Journal of medicinal chemistry.

[158]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[159]  J. Gruzelier,et al.  Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. , 1988, Archives of general psychiatry.

[160]  J. Olney,et al.  Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists. , 1987, European journal of pharmacology.

[161]  P. Ascher,et al.  Glycine potentiates the NMDA response in cultured mouse brain neurons , 1987, Nature.

[162]  R. Dingledine,et al.  Involvement of N-methyl-d-aspartate Receptors in Involvement of N-methyl-d-aspartate Receptors in Epileptiform Bursting in the Rat Hippocampal Slice , 2008 .

[163]  James V. Hinrichs,et al.  Ketamine: behavioral effects of subanesthetic doses. , 1984, Journal of clinical psychopharmacology.

[164]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[165]  I. Whishaw,et al.  Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. , 1983, The Journal of nervous and mental disease.

[166]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[167]  S. Zukin,et al.  Adverse reactions to ketamine Anaesthesia , 1981, Anaesthesia.

[168]  R. Zukin,et al.  Specific [3H]phencyclidine binding in rat central nervous system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[169]  S. J. Young,et al.  Phencyclidine-induced psychosis. , 1978, The American journal of psychiatry.

[170]  R. Post,et al.  Cocaine, kindling, and psychosis. , 1976, The American journal of psychiatry.

[171]  D. Greenblatt,et al.  A controlled trial of amantadine in drug-induced extrapyramidal disorders. , 1976, Psychopharmacology bulletin.

[172]  S. Vale,et al.  Amantadine in depression. , 1971, Lancet.

[173]  R. Knill-Jones,et al.  Controlled trial of amantadine hydrochloride in Parkinson's disease. , 1970, Lancet.

[174]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[175]  G A Gutman,et al.  Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder? , 1998, Molecular Psychiatry.

[176]  P. Herrling Excitatory amino acids : clinical results with antagonists , 1997 .

[177]  P. Skolnick,et al.  Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. , 1996, Pharmacopsychiatry.

[178]  M. Rogawski,et al.  Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. , 1996, The Journal of pharmacology and experimental therapeutics.

[179]  L. Havelec,et al.  Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. , 1996, Neuropsychobiology.

[180]  D. Lovinger,et al.  Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. , 1995, Clinical neuroscience.

[181]  C. Finch,et al.  Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. , 1995, Journal of molecular neuroscience : MN.

[182]  R. Spanagel,et al.  Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. , 1995, Journal of neural transmission. Supplementum.

[183]  T. Soderling Calcium-dependent protein kinases in learning and memory. , 1995, Advances in second messenger and phosphoprotein research.

[184]  C. Randolph,et al.  D‐Cycloserine Treatment of Alzheimer Disease , 1994, Alzheimer disease and associated disorders.

[185]  A. Korczyn,et al.  Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[186]  R. Sapolsky Chapter 2 Glucocorticoids, hippocampal damage and the glutamatergic synapse , 1990 .

[187]  G. E. Alexander,et al.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. , 1990, Progress in brain research.

[188]  R. Schottenfeld,et al.  Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients. , 1990, NIDA research monograph.

[189]  S. A. Turkanis,et al.  Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. , 1989, Life sciences.

[190]  F. Tennant,et al.  Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. , 1987, Archives of internal medicine.